{"id":742046,"date":"2010-10-29T06:00:00","date_gmt":"2010-10-29T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/"},"modified":"2026-08-10T13:01:14","modified_gmt":"2026-08-10T17:01:14","slug":"merck-announces-third-quarter-2010-financial-results","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/","title":{"rendered":"Merck Announces Third-Quarter 2010 Financial Results"},"content":{"rendered":"<ul>\n<li>         Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.11, for          the Quarter       <\/li>\n<li>         Strong Sales of Key Pharmaceutical Products; Solid Performance by          Consumer Care and Animal Health Units       <\/li>\n<li>         New Product Launches and Progressing Pipeline Drive Business Momentum       <\/li>\n<li>         On Track to Meet Synergy Target of $3.5 Billion in Annual Savings by          End of 2012       <\/li>\n<li>         Raised Lower End of 2010 Non-GAAP EPS Target Range Due to Solid          Year-to-Date Performance; Long-Term Non-GAAP EPS Growth Rate Target          Reaffirmed       <\/li>\n<\/ul>\n<p>Merck &amp; Co., Inc. (NYSE: MRK) today announced financial results for the        third quarter of 2010. The company reported non-GAAP (generally accepted        accounting principles) earnings per share (EPS) for the third quarter of        $0.85, which excludes purchase accounting adjustments, restructuring        costs, merger-related expenses and a $950 million legal reserve.        Third-quarter GAAP EPS was $0.11.     <\/p>\n<p>       Worldwide sales for the third quarter of 2010 were $11.1 billion. Net        income<sup>1<\/sup> for the third quarter was $342 million.     <\/p>\n<p>       For the first nine months of 2010, worldwide sales were $33.9 billion        and net income was $1.4 billion.     <\/p>\n<p>       A reconciliation of EPS as reported in accordance with GAAP to EPS,        excluding certain items, is provided in the table that follows. The        third quarter and year-to-date 2009 results below reflect legacy Merck        on a stand-alone basis.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\" rowspan=\"2\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"3\">           <b>Quarter Ended Sept. 30<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"3\">           <b>Nine Months Ended Sept. 30<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           2010         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           2009         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           2010         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           2009         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP EPS<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ 0.11<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ 1.61<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ 0.44<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ 3.03<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             EPS impact of items*           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.74         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (0.71)         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2.10         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (0.56)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Non-GAAP EPS that excludes certain items listed below<\/b><sup><b>2<\/b><\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$ 0.85<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$ 0.90<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$ 2.54<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$ 2.47<\/b>           <\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <i>* Amount calculated as follows (in millions except per share              amounts)<\/i>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Third-<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Quarter<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>2010<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Third-<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Quarter<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>2009<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Nine Months <\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Ended<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Sept.\u00a030,\u00a02010<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Nine Months <\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Ended<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Sept.\u00a030,\u00a02009<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Purchase accounting adjustments         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 1,540         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 5,576         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ &#8212;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Merger restructuring program         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           384         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,497         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Costs related to other restructuring programs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           117         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           135         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           484         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Merger-related costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           64         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           144         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           235         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           257         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Legal reserve         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           950         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           950         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Gain on AstraZeneca&#8217;s asset option exercise         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (443)         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Gain from sale of interest in Merial         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (2,763)         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (2,763)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Net decrease (increase) in income before taxes         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,941         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (2,502)         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           7,950         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (2,022)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Income tax (benefit) expense<sup>3<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (638)         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           986         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (1,383)         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           848         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Decrease (increase) in net income         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 2,303         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ (1,516)         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 6,567         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ (1,174)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           <b>EPS impact of items<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ 0.74<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ (0.71)<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ 2.10<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ (0.56)<\/b>         <\/td>\n<\/tr>\n<\/table>\n<p>       &#8220;We are pleased with the third quarter as well as our overall execution        during Merck&#8217;s first year as a combined company following the merger,&#8221;        said Richard T. Clark, chairman and chief executive officer. &#8220;Our key        products are performing well, and at the same time we are launching new        products, advancing our robust R&amp;D pipeline and achieving our important        merger synergies. One year later, Merck is a much stronger, unified        organization that is well-positioned for the future.&#8221;     <\/p>\n<p>       <b>Select Business Highlights<\/b>     <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">         New four-year data on odanacatib, the company&#8217;s investigational          treatment for osteoporosis in post-menopausal women, was presented          last week at the American Society for Bone and Mineral Research annual          meeting. Clinical and preclinical studies continue to provide data on          the potential of odanacatib to increase bone density, cortical          thickness and bone strength when treating osteoporosis.       <\/li>\n<li class=\"bwlistitemmargb\">         Also, full data results for two pivotal late-stage studies for          boceprevir, for the treatment of hepatitis C, will be presented Nov. 1          and 2 at the annual meeting of the American Association for the Study          of Liver Disease.       <\/li>\n<li class=\"bwlistitemmargb\">         Safety and efficacy data from the DEFINE study for anacetrapib for the          treatment of atherosclerosis will be presented in a late-breaker          presentation on Nov. 17, at the American Heart Association&#8217;s          Scientific Sessions.       <\/li>\n<li class=\"bwlistitemmargb\">         In the quarter, the company also launched three new medicines: the          intravenous (IV) formulation of BRINAVESS (vernakalant) for the          treatment of atrial fibrillation in adults in the European Union (EU),          Iceland and Norway; DULERA (mometasone furoate and formoterol fumarate          dihydrate) for the treatment of asthma in the United States; and DAXAS          (roflumilast) for the treatment of symptomatic COPD in Canada and          certain European markets, through a partnership.       <\/li>\n<li class=\"bwlistitemmargb\">         The company is making progress growing its business in emerging          markets, with 18 percent of sales from human health pharmaceuticals          and vaccines coming from these markets in the quarter.       <\/li>\n<li class=\"bwlistitemmargb\">         Merck continues to secure strategic research and development          collaborations, including agreements this quarter with Alectos          Therapeutics and NicOx, to develop targeting technologies for new          compounds. In addition, the company signed an agreement to allow          Lundbeck to distribute SYCREST (asenapine), Merck&#8217;s treatment for          bipolar disorder, in all markets outside the United States, China and          Japan.       <\/li>\n<li class=\"bwlistitemmargb\">         Merck&#8217;s subsidiary, Schering-Plough (Ireland) Company and Centocor          Ortho Biotech Inc., a Johnson &amp; Johnson subsidiary, have concluded the          arbitration hearing regarding Remicade and Simponi, and will file          post-hearing briefs and present arguments to the arbitration panel in          late December. Merck anticipates a decision in 2011.       <\/li>\n<\/ul>\n<p>       <b>Third-Quarter Financial Results<\/b>     <\/p>\n<p>       The following supplemental combined third-quarter 2009 non-GAAP sales        are adjusted to reflect a full quarter of legacy Merck and legacy        Schering-Plough combined results. This supplemental information is        provided to enhance investors&#8217; understanding of the company&#8217;s products        and overall business performance and should be considered in addition        to, but not in lieu of, sales recorded in accordance with GAAP.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>3Q10<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>3Q09<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<p class=\"bwcellpmargin\">             <b>Adj.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>3Q09<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Supp. Comb.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Non-GAAP<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>3Q09<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Total Sales           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 11,125         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 6,050         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 5,481         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 11,531         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Human Health<sup>4<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           9,660         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           5,676         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           4,425         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           10,101         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Animal Health           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           687         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           664         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           664         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Consumer Care<sup>4<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           291         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           283         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           283         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Other Revenues<sup>5<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           487         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           374         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           109         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           483         <\/td>\n<\/tr>\n<\/table>\n<p>       The third quarter 2010 results discussed below reflect the performance        of the combined company. The increases noted in quarterly comparisons        are largely due to the inclusion of legacy Schering-Plough operations in        2010 results, but not in 2009 results.     <\/p>\n<p>       Materials and production costs were $4.2 billion for the third quarter        of 2010, compared to $1.4 billion for the third quarter of 2009. The        third quarter of 2010 includes $1.4 billion of costs related to the        amortization of intangible assets and purchase accounting adjustments to        inventories as a result of the merger. The third quarters of 2010 and        2009 include $44 million and $27 million, respectively, for costs        associated with restructuring programs. The gross margin was 62.3        percent for the third quarter of 2010, reflecting a 12.6 percentage        point unfavorable impact from the purchase accounting adjustments and        restructuring costs noted above.     <\/p>\n<p>       Marketing and administrative expenses were $3.2 billion for the third        quarter of 2010, which include $130 million of restructuring costs and        $64 million of merger-related costs. Marketing and administrative costs        were $1.7 billion for the third quarter of 2009. Costs for the third        quarter of 2009 include $56 million of merger-related expenses.     <\/p>\n<p>       Research and development expenses were $2.3 billion for the third        quarter of 2010, which include $189 million for in-process research and        development impairments and $163 million for restructuring activities.        Expenses for 2009 were $1.3 billion for the quarter, which include $48        million of costs for restructuring activities.     <\/p>\n<p>       Restructuring costs, primarily related to employee separations, were $50        million for the third quarter of 2010 compared with $42 million for the        third quarter of 2009.     <\/p>\n<p>       Total overall costs associated with the company&#8217;s global restructuring        programs included in materials and production, marketing and        administrative, research and development, and restructuring costs were        $387 million and $117 million for the third quarters of 2010 and 2009,        respectively, primarily comprised of employee separation costs and        accelerated depreciation.     <\/p>\n<p>       Equity income from affiliates was $236 million in the third quarter of        2010. Equity income from affiliates no longer reflects any contribution        from the Merck\/Schering-Plough partnership or from Merial Limited.     <\/p>\n<p>       Other (income) expense was $1.1 billion of expense in the third quarter        of 2010, which includes the unfavorable impact of a $950 million legal        reserve, compared with $2.8 billion of income in the third quarter of        2009, which included the gain on the sale of Merck&#8217;s interest in Merial        Limited. The company has established the legal reserve in connection        with an anticipated resolution of the previously disclosed investigation        by the U.S. Attorney&#8217;s Office for the District of Massachusetts related        to VIOXX. Merck&#8217;s discussions with the government are ongoing. Until        they are concluded, there can be no certainty about a definitive        resolution.     <\/p>\n<p>       The GAAP effective tax rate of 25.3 percent for the third quarter of        2010 reflects the impact of the legal reserve referred to above,        restructuring costs and purchase accounting adjustments. It also        includes a $380 million tax benefit from changes in a foreign entity&#8217;s        tax rate that became effective in the third quarter, resulting in a        reduction in deferred tax liabilities on product intangibles recorded in        conjunction with the merger. The non-GAAP effective tax rate, which        excludes all these items, was 22.2 percent for the quarter.     <\/p>\n<p>       <b>Financial Targets<\/b>     <\/p>\n<p>       For 2010, Merck raised the lower end of the non-GAAP EPS range and is        now targeting a range of $3.31 to $3.39, excluding certain items, and a        2010 GAAP EPS range of $0.66 to $0.97. The 2010 non-GAAP range excludes        purchase accounting adjustments, restructuring and merger-related costs,        the first-quarter tax charge related to U.S. health care reform        legislation, the second-quarter gain on AstraZeneca&#8217;s asset option        exercise, and the third-quarter $950 million legal reserve. EPS and        other financial targets for 2010 assume that Merck will retain full        rights to REMICADE and SIMPONI in the applicable markets.     <\/p>\n<p>       A reconciliation of anticipated 2010 EPS as reported in accordance with        GAAP to non-GAAP EPS that excludes certain items is provided in the        table that follows:     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Full-Year 2010<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP EPS<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl2 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$0.66 to $0.97<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             EPS impact of items*           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl2 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             $2.65 to $2.42           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           <b>Non-GAAP EPS that excludes certain items listed below<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl2 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$3.31 to $3.39<\/b>           <\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignr bwsinglebottom\">           <i>* Amount calculated as follows (in millions except per share            amounts)<\/i>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>Full-Year 2010<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Purchase accounting adjustments         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignr bwsinglebottom\">           $7,000 to $6,500         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Costs related to restructuring programs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignr bwsinglebottom\">           2,000 to 1,700         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Merger-related costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwvertalignt bwalignr bwsinglebottom\">           350 to 250         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Legal reserve         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           950         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Gain on AstraZeneca&#8217;s asset option exercise         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (443)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Net decrease (increase) in income before taxes         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignr bwsinglebottom\">           9,857 to 8,957         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Income tax (benefit) expense<sup>6<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwvertalignt bwalignr bwsinglebottom\">           (1,593) to (1,423)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Decrease (increase) in net income         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwvertalignt bwalignr bwsinglebottom\">           $8,264 to $7,534         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           <b>EPS impact of items<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignr bwsinglebottom\">           <b>$2.65 to $2.42<\/b>         <\/td>\n<\/tr>\n<\/table>\n<p>       Merck said it expects full-year 2010 revenue to be between $45.4 billion        and $46.1 billion, including the impact of U.S. health care reform        legislation. For the full year 2010, the increased Medicaid rebates        (including Managed Medicaid) and other impacts are expected to reduce        revenue by approximately $170 million, which includes a third-quarter        2010 impact of approximately $43 million and $120 million for the first        nine months of 2010.     <\/p>\n<p>       Non-GAAP research and development expense, which excludes joint        ventures, is anticipated to be approximately $8.2 billion to $8.6        billion for the full year of 2010. This target excludes the portion of        the restructuring costs and any in-process R&amp;D impairment charges        included in research and development expense for 2010.     <\/p>\n<p>       Merck continues to estimate that its consolidated non-GAAP 2010 tax rate        will be approximately 22 percent to 24 percent.     <\/p>\n<p>       Merck continues to target a high single-digit non-GAAP EPS compound        annual growth rate for the combined company from 2009 to 2013 when        compared to Merck&#8217;s 2009 non-GAAP EPS. As the company has previously        said, the longer-term target is applicable regardless of the assumptions        made for the REMICADE and SIMPONI business.     <\/p>\n<p>       <b>Product Performance \u2013 Human Health<\/b>     <\/p>\n<p>       The sales figures discussed below for legacy Schering-Plough products        are reported on a GAAP basis, which represents sales for the third        quarter of 2010 only.     <\/p>\n<p>       <i>Bone, Respiratory, Immunology and Dermatology<\/i>     <\/p>\n<p>       Worldwide sales of SINGULAIR (montelukast sodium), a once-a-day oral        medicine indicated for the chronic treatment of asthma and the relief of        symptoms of allergic rhinitis, were $1.2 billion for the third quarter        of 2010, an increase of 12 percent compared with the third quarter of        2009.     <\/p>\n<p>       Global sales of NASONEX (mometasone furoate monohydrate), nasal spray,        an inhaled nasal corticosteroid for the treatment of nasal allergy        symptoms, were $259 million for the third quarter of 2010.     <\/p>\n<p>       Sales of REMICADE (infliximab) were $661 million for the third quarter        of 2010. REMICADE is a treatment for inflammatory diseases which is        marketed by Merck in countries outside the United States (except in        Japan and certain other Asian markets). In addition, SIMPONI        (golimumab), a once-monthly, subcutaneous treatment for certain        inflammatory diseases, has been launched in 18 countries, and launches        in other international markets are planned.     <\/p>\n<p>       <i>Cardiovascular<\/i>     <\/p>\n<p>       Global sales of ZETIA (ezetimibe) and VYTORIN (ezetimibe\/simvastatin)        were $571 million and $485 million, respectively, for the third quarter        of 2010. Combined global sales of ZETIA and VYTORIN were $1.1 billion        for the third quarter of 2010.     <\/p>\n<p>       <i>Diabetes and Obesity<\/i>     <\/p>\n<p>       JANUVIA (sitagliptin), Merck&#8217;s DPP-4 inhibitor for the treatment of type        2 diabetes, recorded worldwide sales of $600 million during the third        quarter of 2010, representing a 22 percent increase compared with the        same quarter in 2009. JANUMET (sitagliptin\/metformin hydrochloride), a        single tablet that targets all three key defects of type 2 diabetes,        achieved worldwide sales of $247 million during the quarter, an increase        of 43 percent compared with the third quarter 2009. The JANUVIA\/JANUMET        combined franchise had sales of $847 million during the third quarter of        2010, an increase of 28 percent compared to the same quarter in 2009.     <\/p>\n<p>       <i>Infectious Disease<\/i>     <\/p>\n<p>       ISENTRESS (raltegravir), an HIV integrase inhibitor for use in        combination with other antiretroviral agents for the treatment of HIV-1        infection, reported worldwide sales of $278 million for the third        quarter of 2010, an increase of 41 percent compared with the third        quarter of 2009.     <\/p>\n<p>       Worldwide sales of PEGINTRON (peginterferon alfa-2b) for chronic        hepatitis C were $168 million for the third quarter of 2010.     <\/p>\n<p>       <i>Diversified Brands<\/i>     <\/p>\n<p>       Merck&#8217;s diversified brands are human health pharmaceutical products that        are approaching the expiration of their marketing exclusivity or are no        longer protected by patents in developed markets, but continue to be a        core part of the company&#8217;s offering in other markets around the world.     <\/p>\n<p>       Global sales of Merck&#8217;s antihypertensive medicines, COZAAR (losartan        potassium) and HYZAAR<sup>7<\/sup> (losartan potassium and        hydrochlorothiazide), were $423 million for the third quarter of 2010,        representing a 51 percent decrease compared with the third quarter of        2009. The company continues to experience a decline in COZAAR\/HYZAAR        sales since these medicines have lost marketing exclusivity in the        United States and in major European markets.     <\/p>\n<p>       <i>Neuroscience and Ophthalmology<\/i>     <\/p>\n<p>       Global sales of MAXALT (rizatriptan benzoate), Merck&#8217;s tablet for the        treatment of acute migraine, were $133 million for the third quarter of        2010, an 8 percent decrease from the same quarter last year.     <\/p>\n<p>       <i>Oncology<\/i>     <\/p>\n<p>       Sales of TEMODAR (temozolomide), a treatment for certain types of brain        tumors, were $254 million for the third quarter of 2010.     <\/p>\n<p>       Sales of CAELYX (pegylated liposomal doxorubicin hydrochloride) for the        treatment of ovarian cancer, metastatic breast cancer and Kaposi&#8217;s        sarcoma, were $70 million for the third quarter of 2010. As previously        disclosed, marketing rights for CAELYX will transition to Johnson &amp;        Johnson as of Dec. 31, 2010.     <\/p>\n<p>       <i>Vaccines<\/i><sup><i>8<\/i><\/sup>     <\/p>\n<p>       Total sales as recorded by Merck of its cervical cancer vaccine,        GARDASIL (human papillomavirus (HPV) quadrivalent (types 6, 11, 16, 18)        vaccine, recombinant), were $316 million for the third quarter of 2010,        a 2 percent increase from the same quarter in 2009. Sales, in part,        benefited from the timing of certain public sector sales.     <\/p>\n<p>       Worldwide sales of Merck&#8217;s other viral vaccines, which include VARIVAX        (varicella virus vaccine live), M-M-R II (measles, mumps and rubella        virus vaccine live) and PROQUAD (measles, mumps, rubella and varicella        virus vaccine live), as recorded by Merck, were $434 million for the        third quarter of 2010, a decrease of 6 percent compared with the same        period a year earlier.     <\/p>\n<p>       ZOSTAVAX (zoster vaccine live), the company\u2019s vaccine to help prevent        shingles (herpes zoster), recorded sales of $23 million for the third        quarter of 2010 compared with $84 million for the third quarter of 2009.        Sales during the quarter were limited by continuing supply constraints.     <\/p>\n<p>       <i>Women&#8217;s Health and Endocrine<\/i>     <\/p>\n<p>       Global sales of NUVARING (etonogestrel\/ethinyl estradiol vaginal ring),        a contraceptive product, were $134 million for the third quarter of 2010.     <\/p>\n<p>       Sales of FOLLISTIM\/PUREGON (follitropin beta injection), a fertility        treatment, were $119 million for the third quarter of 2010.     <\/p>\n<p>       <b>Product Performance \u2015 Animal Health<\/b>     <\/p>\n<p>       Animal Health sales totaled $687 million for the third quarter of 2010,        reflecting continued solid performance among poultry, swine and aquatic        products. Animal Health includes pharmaceutical and vaccine products for        the prevention, treatment and control of disease in all major farm and        companion animal species. Merck&#8217;s Animal Health business is subject to a        proposed joint venture with sanofi-aventis which the company expects to        close in the first quarter of 2011.     <\/p>\n<p>       <b>Product Performance \u2015 Consumer Care<\/b>     <\/p>\n<p>       Consumer Care sales were $291 million for the third quarter of 2010,        which reflect continued strong performance of a number of key brands        including DR. SCHOLL&#8217;s, CLARITIN and COPPERTONE. Consumer Care includes        footcare and suncare consumer products, and a variety of        over-the-counter medicines.     <\/p>\n<p>       <b>Total Employees<\/b>     <\/p>\n<p>       As of Sept. 30, Merck had approximately 93,000 employees worldwide.     <\/p>\n<p>       <b>Explanatory Note<\/b>     <\/p>\n<p>       Supplemental combined non-GAAP sales are provided in the attached        schedules at the end of this news release to reflect the revenues of the        company&#8217;s product sales on a comparable basis to periods prior to the        merger. Merck has defined supplemental combined non-GAAP sales as GAAP        sales adjusted to reflect a full quarter of Merck and Schering-Plough        performance as if the merger closed at the beginning of the periods        indicated in the applicable table. This supplemental information is        provided to enhance investors&#8217; understanding of the company&#8217;s products        and overall business performance. This information should be considered        in addition to, but not in lieu of, sales recorded in accordance with        GAAP. Supplemental combined non-GAAP sales are available in Tables 3 and        3a as part of this news release, and additional information is included        in the 8-K filing today.     <\/p>\n<p>       <b>Earnings Conference Call<\/b>     <\/p>\n<p>       Investors are invited to a live audio webcast of Merck&#8217;s third-quarter        earnings conference call today at 8:00 a.m. EDT by visiting Merck&#8217;s Web        site, <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;esheet=6488925&amp;lan=en-US&amp;anchor=www.merck.com%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;index=1&amp;md5=5e5c8fbb125958807ab96b6a1bc3c854\">www.merck.com\/investors\/events-and-presentations\/home.html<\/a>.        Institutional investors and analysts can participate in the call by        dialing (706) 758-9927 or (877) 381-5782. Journalists are invited to        listen in on the call by dialing (706) 758-9928 or (800) 399-7917. A        replay of the webcast will be available starting at 11 a.m. EDT today        through 5 p.m. EDT on Nov. 6. To listen to the replay, dial (706)        645-9291 or (800) 642-1687 and enter ID No. 11269659.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships that        donate and deliver our products to the people who need them. For more        information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=6488925&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=2&amp;md5=96a4e3067bcef5abd3287196e9895dc6\">www.merck.com<\/a>.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2009 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6488925&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=a9515b9a8c67265e3bb500aa0f3a9052\">www.sec.gov<\/a>).     <\/p>\n<p>       <sup>1<\/sup> Net income attributable to Merck &amp; Co., Inc.     <\/p>\n<p>       <sup>2 <\/sup>Merck is providing information on 2010 and 2009 non-GAAP        earnings per share that excludes certain items because of the nature of        these items and the impact they have on the analysis of underlying        business performance and trends. Management believes that providing this        information enhances investors&#8217; understanding of the company&#8217;s        performance. This information should be considered in addition to, but        not in lieu of, earnings per share prepared in accordance with GAAP. For        a description of the items, see Tables 2a and 2b, including the related        footnotes, attached to this release.     <\/p>\n<p>       <sup>3 <\/sup>Includes an estimated income tax (benefit) expense on the        reconciling items. In addition, amounts for the three and nine months        ended September 30, 2010 include a $380 million tax benefit from changes        in a foreign entity&#8217;s tax rate, which resulted in a reduction in        deferred tax liabilities on product intangibles recorded in conjunction        with the merger. The amount for the nine months ended September 30, 2010        also reflects a $147 million tax charge related to U.S. health care        reform legislation.     <\/p>\n<p>       <sup>4 <\/sup>Human Health includes worldwide prescription pharmaceutical        sales and consumer product sales excluding the U.S. and Canada. Consumer        Care includes U.S. and Canada consumer product sales.     <\/p>\n<p>       <sup>5 <\/sup>Other revenues are primarily comprised of alliance revenue,        miscellaneous corporate revenues and third party manufacturing sales.        Revenue from AstraZeneca LP recorded by Merck was $345 million in the        third quarter of 2010.     <\/p>\n<p>       <sup>6 <\/sup>Represents an estimated income tax (benefit) expense on the        reconciling items, as well as a $380 million tax benefit from changes in        foreign entity\u2019s tax rate and a $147 million tax charge related to U.S.        health care reform.     <\/p>\n<p>       <sup>7<\/sup> COZAAR and HYZAAR are registered trademarks of E.I. duPont        de Nemours and Company, Wilmington, Del.     <\/p>\n<p>       <sup>8<\/sup> Vaccines in most major European markets are sold through        the company\u2019s joint venture, Sanofi Pasteur MSD, and the results from        the company&#8217;s interest in the joint venture are recorded in equity        income from affiliates.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"13\">\n<p class=\"bwcellpmargin\">             <b>MERCK\u00a0&amp;\u00a0CO., INC.<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"13\">\n<p class=\"bwcellpmargin\">             <b>CONSOLIDATED\u00a0STATEMENT\u00a0OF\u00a0OPERATIONS &#8211; GAAP<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"13\">\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS\u00a0IN\u00a0MILLIONS, EXCEPT\u00a0PER\u00a0SHARE\u00a0FIGURES)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"13\">\n<p class=\"bwcellpmargin\">             <b>(UNAUDITED)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"13\">\n<p class=\"bwcellpmargin\">             <b>TABLE\u00a01<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">           <b>GAAP<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">           <b>GAAP<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>3Q10<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>3Q09<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>% Change<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>YTD 2010<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>YTD 2009<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>% Change<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Sales         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 11,124.9         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 6,049.7         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           84%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 33,893.3         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 17,334.8         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           96%         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Costs, Expenses and Other         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Materials and production <sup>(1)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,191.4         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,430.3         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           <b>*<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           13,955.9         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,118.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           <b>*<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Marketing and administrative <sup>(2)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,217.9         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,725.5         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           86%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           9,666.8         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5,088.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           90%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Research and development <sup>(3)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,296.4         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,254.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           83%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6,474.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,873.5         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           67%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Restructuring costs <sup>(4)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49.6         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           42.4         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           17%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           863.6         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           144.1         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           <b>*<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Equity income from affiliates <sup>(5)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (236.4)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (688.2)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -66%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (416.8)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (1,861.2)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -78%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Other (income) expense, net <sup>(6)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,108.3         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (2,791.1)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           <b>*<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           995.6         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (2,854.7)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           <b>*<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Income Before Taxes         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           497.7         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5,076.8         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -90%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,354.2         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           8,827.1         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -73%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Taxes on Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           126.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,621.5         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           872.2         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,327.7         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           371.7         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,455.3         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -89%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,482.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6,499.4         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -77%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Less: Net Income Attributable to Noncontrolling Interests         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           30.1         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           31.0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           89.3         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           93.8         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income Attributable to Merck &amp; Co., Inc.         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 341.6         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 3,424.3         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -90%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 1,392.7         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 6,405.6         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -78%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Earnings per Common Share Assuming Dilution <sup>(7)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 0.11         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 1.61         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -93%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 0.44         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 3.03         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -85%         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Average Shares Outstanding Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,101.6         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,113.7         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,123.3         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,110.6         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Tax Rate <sup>(8)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           25.3%         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           31.9%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           37.1%         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           26.4%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           *\u2265 100%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           (1) The third quarter and first nine months of 2010 includes $1.4            billion and $5.4 billion, respectively, of expenses for the            amortization of intangible assets and the amortization of purchase            accounting adjustments to inventories recognized as a result of the            merger. Also includes restructuring costs of $44 million and $27            million in the third quarter of 2010 and 2009, respectively, and            $325 million and $96 million for the first nine months of 2010 and            2009, respectively, primarily related to accelerated depreciation.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           (2) The third quarter and the first nine months of 2010 includes            restructuring costs of $130 million primarily related to accelerated            depreciation. Also reflects merger-related costs of $64 million and            $56 million in the third quarter of 2010 and 2009, respectively, and            $218 million and $106 million in the first nine months of 2010 and            2009, respectively.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           (3) Includes restructuring costs of $163 million and $48 million in            the third quarter of 2010 and 2009, respectively, and $313 million            and $244 million in the first nine months of 2010 and 2009,            respectively, primarily related to accelerated depreciation. In            addition, expenses for the third quarter and the first nine months            of 2010 include $189 million and $216 million, respectively, of            in-process research and development (\u201cIPR&amp;D\u201d) impairment charges.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           (4) Represents separation and other related costs associated with            restructuring activities.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           (5) In 2010, equity income from affiliates no longer reflects any            contribution from the Merck\/Schering-Plough partnership, which is            now wholly-owned by the company as a result of the merger, or from            Merial Limited due to the sale of Merck\u2019s interest in 2009.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           (6) The change in other (income) expense, net in the third quarter            of 2010 is primarily due to a $2.8 billion gain recognized on the            disposition of Merck\u2019s interest in Merial Limited in 2009, a $950            million legal reserve recorded in 2010, as well as lower realized            gains on the company\u2019s investment portfolio in 2010. Other (income)            expense, net reflects merger-related costs of $88 million in the            third quarter of 2009.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"13\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           The change in other (income) expense, net for the first nine months            of 2010 is primarily the result of a $2.8 billion gain on the            disposition of Merck\u2019s interest in Merial Limited recognized in            2009. In addition, during the first nine months of 2010, the company            recognized a $950 million legal reserve, higher interest expense and            lower interest income largely attributable to the financing of the            merger, lower realized gains on the company&#8217;s investment portfolio            and higher exchange losses due to the Venezuelan currency            devaluation. Partially offsetting these items was $443 million of            income recognized upon AstraZeneca\u2019s asset option exercise and            income on the settlement of certain disputed royalties recorded in            2010. Other (income) expense, net reflects merger-related costs of            $17 million and $151 million in the first nine months of 2010 and            2009, respectively.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           (7) The company calculates earnings per share pursuant to the            two-class method which requires the allocation of net income between            common shareholders and participating security holders. Net income            attributable to Merck &amp; Co., Inc. common shareholders used to            calculate earnings per common share assuming dilution was $340.4            million and $3,412.6 million for the third quarter of 2010 and 2009,            respectively, and was $1,387.4 million and $6,385.4 million for the            first nine months of 2010 and 2009, respectively.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"13\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">\n<p class=\"bwcellpmargin\">             (8) The effective tax rate of 25.3% for the third quarter of 2010              reflects the net unfavorable impact of approximately 3 percentage              points resulting from the legal reserve, restructuring costs and              purchase accounting adjustments, partially offset by a $380              million tax benefit from changes in a foreign entity&#8217;s tax rate              that became effective in the third quarter, resulting in a              reduction in deferred tax liabilities on product intangibles              recorded in conjunction with the merger.\u00a0\u00a0The effective tax rate              of 37.1% for the first nine months of 2010 reflects the net              unfavorable impact of approximately 15 percentage points resulting              from purchase accounting charges, the impact of a $146.5 million              charge associated with a change in tax law that requires taxation              of the prescription drug subsidy of the company&#8217;s retiree health              benefit plans which was enacted in the first quarter of 2010 as              part of U.S. health care reform legislation, as well as by the              impact of AstraZeneca&#8217;s asset option exercise, restructuring              charges and a legal reserve, partially offset by the favorable              impact of the $380 million tax benefit noted above.           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"13\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"13\">           The effective tax rate of 31.9% for the third quarter of 2009            reflects a net unfavorable rate impact of approximately 5 percentage            points reflecting the unfavorable rate impact of the gain on the            sale of Merck\u2019s interest in Merial, partially offset by the            favorable impact of the closing of a tax exam. The effective tax            rate of 26.4% for the first nine months of 2009 reflects a net            unfavorable rate impact of approximately 1 percentage point            reflecting the unfavorable impact of the gain on the sale of Merck\u2019s            interest in Merial, partially offset by the favorable impact of 2009            tax settlements, including the settlement reached with the Canada            Revenue Agency in the first quarter of 2009, as well as the closing            of a tax exam.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>CONSOLIDATED\u00a0STATEMENT\u00a0OF\u00a0OPERATIONS<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>GAAP\u00a0TO\u00a0NON-GAAP RECONCILIATION<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>THIRD\u00a0QUARTER\u00a02010<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS\u00a0IN\u00a0MILLIONS, EXCEPT PER\u00a0SHARE\u00a0FIGURES)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>(UNAUDITED)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>Table 2a<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>GAAP<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">\n<p class=\"bwcellpmargin\">             <b>Purchase Accounting<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <sup><b>(1)<\/b><\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">\n<p class=\"bwcellpmargin\">             <b>Restructuring Costs <\/b><sup>(2)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">           <b>Merger-Related Costs <\/b><sup>(3)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">\n<p class=\"bwcellpmargin\">             <b>Certain\u00a0Other Items\u00a0<\/b><sup>(4)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">           <b>Adjustment Subtotal<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Non-GAAP<\/b>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Sales         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$ 11,124.9<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 11,124.9         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Materials and production         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>4,191.4<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,350.8         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           44.4         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,395.2         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,796.2         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Marketing and administrative         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3,217.9<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           130.5         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           63.7         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           194.2         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,023.7         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Research and development         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2,296.4<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           189.5         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           162.8         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           352.3         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,944.1         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Restructuring costs         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>49.6<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49.6         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49.6         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Equity income from affiliates         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(236.4)<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (236.4)         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Other (income) expense, net         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,108.3<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           950.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           950.0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           158.3         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Income Before Taxes         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>497.7<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (1,540.3)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (387.3)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (63.7)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (950.0)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (2,941.3)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,439.0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Taxes on Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>126.0<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (638.3)         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <sup>(5)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           764.3         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>371.7<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (2,303.0)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,674.7         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Less: Net Income Attributable to Noncontrolling Interests         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>30.1<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           30.1         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income Attributable to Merck &amp; Co., Inc.         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$ 341.6<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ (2,303.0)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 2,644.6         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Earnings per Common Share Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ 0.11<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ (0.74)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 0.85         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <sup>(6)<\/sup>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Average Shares Outstanding Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3,101.6<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,101.6         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Tax Rate         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>25.3%<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           22.2%         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           Merck is providing non-GAAP information that excludes certain items            because of the nature of these items and the impact they have on the            analysis of underlying business performance and trends. Management            believes that providing this information enhances investors&#8217;            understanding of the company&#8217;s performance. This information should            be considered in addition to, but not in lieu of, information            prepared in accordance with GAAP.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (1) Amounts included in materials and production costs reflect            expenses for the amortization of intangible assets and the            amortization of purchase accounting adjustments to inventories            recognized as a result of the merger. Amounts included in research            and development expense represent in-process research and            development (\u201cIPR&amp;D\u201d) impairment charges.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (2) Amounts primarily include employee separation costs and            accelerated depreciation associated with facilities to be sold or            closed.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (3) Merger-related costs include transaction and integration costs            associated with the merger.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (4) Included in other (income) expense, net is a $950 million legal            reserve.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (5) Includes a $380 million tax benefit from changes in a foreign            entity&#8217;s tax rate, as well as the estimated tax impact on the            reconciling items.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (6) The company calculates earnings per share pursuant to the            two-class method which requires the allocation of net income between            common shareholders and participating security holders. Net income            attributable to Merck &amp; Co., Inc. common shareholders used to            calculate non-GAAP earnings per common share assuming dilution was            $2,634.5 million for the third quarter of 2010.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>MERCK\u00a0&amp;\u00a0CO., INC.<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>CONSOLIDATED\u00a0STATEMENT\u00a0OF\u00a0OPERATIONS<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>GAAP\u00a0TO\u00a0NON-GAAP\u00a0RECONCILIATION<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>NINE\u00a0MONTHS\u00a0ENDED\u00a0SEPTEMBER\u00a030, 2010<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS\u00a0IN\u00a0MILLIONS, EXCEPT\u00a0PER\u00a0SHARE\u00a0FIGURES)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>(UNAUDITED)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             <b>Table 2b<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>GAAP<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">           <b>Purchase Accounting <\/b><sup><b>(1)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">           <b>Restructuring Costs <\/b><sup>(2)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">           <b>Merger-Related Costs <\/b><sup>(3)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">\n<p class=\"bwcellpmargin\">             <b>Certain\u00a0Other\u00a0<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Items\u00a0<\/b><sup>(4)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignc\">           <b>Adjustment Subtotal<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Non-GAAP<\/b>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Sales         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$ 33,893.3<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 33,893.3         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Materials and production         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>13,955.9<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5,360.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           325.5         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5,685.5         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           8,270.4         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Marketing and administrative         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>9,666.8<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           130.5         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           218.0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           348.5         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           9,318.3         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Research and development         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>6,474.0<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           216.2         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           312.7         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           528.9         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5,945.1         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Restructuring costs         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>863.6<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           863.6         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           863.6         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Equity income from affiliates         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(416.8)<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (416.8)         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Other (income) expense, net         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>995.6<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           17.1         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           507.0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           524.1         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           471.5         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Income Before Taxes         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2,354.2<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (5,576.2)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (1,632.3)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (235.1)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (507.0)         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (7,950.6)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           10,304.8         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Taxes on Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>872.2<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (1,383.7)         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <sup>(5)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,255.9         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,482.0<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (6,566.9)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           8,048.9         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Less: Net Income Attributable to Noncontrolling Interests         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>89.3<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           89.3         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income Attributable to Merck &amp; Co., Inc.         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$ 1,392.7<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ (6,566.9)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ 7,959.6         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Earnings per Common Share Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$ 0.44<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $ (2.10)         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 2.54         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <sup>(6)<\/sup>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Average Shares Outstanding Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3,123.3<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,123.3         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Tax Rate         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>37.1%<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           21.9%         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           Merck is providing non-GAAP information that excludes certain items            because of the nature of these items and the impact they have on the            analysis of underlying business performance and trends. Management            believes that providing this information enhances investors&#8217;            understanding of the company&#8217;s performance. This information should            be considered in addition to, but not in lieu of, information            prepared in accordance with GAAP.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (1) Amounts included in materials and production costs reflect            expenses for the amortization of intangible assets and the            amortization of purchase accounting adjustments to inventories            recognized as a result of the merger. Amounts included in research            and development expense represent in-process research and            development (\u201cIPR&amp;D\u201d) impairment charges.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (2) Amounts primarily include employee separation costs and            accelerated depreciation associated with facilities to be sold or            closed.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (3) Merger-related costs include transaction and integration costs            associated with the merger.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (4) Included in other (income) expense, net is a $950 million legal            reserve and a $443 million gain recognized upon AstraZeneca&#8217;s            exercise of the asset option.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">           (5) Includes a $380 million tax benefit from changes in a foreign            entity&#8217;s tax rate, a charge of $146.5 million associated with a            change in tax law that requires taxation of the prescription drug            subsidy of the company&#8217;s retiree health benefit plans which was            enacted in the first quarter of 2010 as part of U.S. health care            reform legislation, as well as the estimated tax impact on the other            reconciling items.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"17\">\n<p class=\"bwcellpmargin\">             (6) The company calculates earnings per share pursuant to the              two-class method which requires the allocation of net income              between common shareholders and participating security holders.              Net income attributable to Merck &amp; Co., Inc. common shareholders              used to calculate non-GAAP earnings per common share assuming              dilution was $7,927.0 million for the nine months ended September              30, 2010.           <\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>MERCK\u00a0&amp;\u00a0CO., INC.<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>FRANCHISE \/ KEY PRODUCT\u00a0SALES<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>THIRD\u00a0QUARTER\u00a02010<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS\u00a0IN\u00a0MILLIONS)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>Table 3<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           The following Table reflects Supplemental Combined Non-GAAP sales            for the prior year which were adjusted to reflect a full quarter of            Merck and Schering-Plough combined results as if the merger closed            as of January 1, 2009.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">           <b>GAAP<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">           <b>Adjustment<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Supp.\u00a0Comb.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Non-GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1  bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">             <b>% Change <\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(3Q10\u00a0GAAP\u00a0vs\u00a0Supp.\u00a0<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Comb.\u00a0Non-GAAP\u00a03Q09)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">           <b>3Q10<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">           <b>3Q09<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">           <b>3Q09<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">           <b>3Q09<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">           <b>TOTAL SALES <\/b><sup><b>(1)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$11,125<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$6,050<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$5,481<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$11,531<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>-4<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">           <b>HUMAN HEALTH <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>9,660<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>5,676<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>4,425<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>10,101<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>-4<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Bone, Resp., Imm., &amp; Dermatology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Singulair         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,215         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,085         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,085         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           12         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Remicade         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           661         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           608         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           608         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Nasonex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           259         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           266         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           266         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Fosamax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           220         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           276         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           276         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -20         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Clarinex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           137         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           164         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           164         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -17         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Arcoxia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           94         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           90         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           90         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Asmanex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           48         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Proventil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           43         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -27         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">             <b>Cardiovascular<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Zetia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           571         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           562         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           563         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Vytorin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           485         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           20         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           505         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           525         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Integrilin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           63         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           74         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           74         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -15         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Diabetes &amp; Obesity<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Januvia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           600         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           491         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           491         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           22         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Janumet         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           247         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           173         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           173         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           43         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Infectious Disease<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Isentress         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           278         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           197         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           197         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           41         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           PegIntron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           168         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           198         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           198         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -15         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Primaxin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           168         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           168         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -20         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Cancidas         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -13         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Invanz         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           91         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           73         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           73         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           25         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Avelox         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           59         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           70         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           70         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -15         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Rebetol         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           64         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           64         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -14         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Crixivan \/ Stocrin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -2         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Diversified Brands<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Cozaar \/ Hyzaar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           423         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           861         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           861         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -51         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Zocor         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           114         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           141         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           141         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -19         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Propecia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           109         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           109         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           109         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8212;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Claritin Rx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           81         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           95         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           95         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -14         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Vasotec \/ Vaseretic         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           69         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           73         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           73         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -4         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Proscar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           58         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           67         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           67         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -14         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Remeron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           50         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           74         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           74         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -32         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Neurosciences &amp; Ophthalmology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Maxalt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           133         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           144         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           144         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Cosopt \/ Trusopt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           114         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           123         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           123         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Subutex \/ Suboxone         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -88         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Oncology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Temodar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           254         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           278         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           278         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Emend         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           91         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           82         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           82         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           11         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Caelyx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           70         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           67         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           67         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Intron A         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           50         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -10         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Vaccines<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           ProQuad, M-M-R II and Varivax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           434         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           462         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           462         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -6         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Gardasil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           316         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           311         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           311         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           RotaTeq         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           119         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           127         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           127         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Pneumovax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           110         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           130         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           130         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -15         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Zostavax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           23         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           84         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           84         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -73         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Women&#8217;s Health &amp; Endocrine<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           NuvaRing         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           134         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           131         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           131         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Follistim \/ Puregon         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           119         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           122         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           122         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Implanon         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           64         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           41         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Cerazette         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           14         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Other Human Health <\/b><sup><b>(3)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,049         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           182         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           834         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,016         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>ANIMAL HEALTH<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>687<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>664<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>664<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>CONSUMER CARE <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>291<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>283<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>283<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           Claritin OTC         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           92         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           85         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           85         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           8         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>Other Revenues <\/b><sup><b>(4)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>487<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>374<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>109<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>483<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwpadb1  bwvertalignt bwalignl\">           Astra         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           345         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           340         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           340         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           <sup>(1)<\/sup> Only select products are shown.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           <sup>(2) <\/sup>Human Health includes worldwide prescription            pharmaceutical sales and consumer product sales excluding the US and            Canada. Consumer Care includes US and Canada consumer product sales.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           <sup>(3)<\/sup> Includes Human Health products not individually shown            above. Other vaccines sales included in Other Human Health were $94            million and $53 million for third quarter 2010 and 2009,            respectively.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           <sup>(4) <\/sup>Other revenues are primarily comprised of alliance            revenue, miscellaneous corporate revenues and third party            manufacturing sales.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           Note: The Company is providing Supplemental Combined Non-GAAP sales            to reflect the revenues of the company&#8217;s product sales on a            comparable basis to periods prior to the merger. Merck has defined            Supplemental Combined Non-GAAP sales as GAAP sales adjusted to            reflect a full quarter of Merck and Schering-Plough performance as            if the merger closed at the beginning of the periods indicated in            this table. This supplemental information is provided to enhance            investors&#8217; understanding of the company&#8217;s sales performance. This            information should be considered in addition to, but not in lieu of,            sales reported in accordance with GAAP.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>MERCK\u00a0&amp;\u00a0CO., INC.<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>FRANCHISE \/ KEY\u00a0PRODUCT\u00a0SALES<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>SEPTEMBER\u00a0YEAR-TO-DATE 2010<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS\u00a0IN\u00a0MILLIONS)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>Table 3a<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           The following Table reflects Supplemental Combined Non-GAAP sales            for the prior year which were adjusted to reflect the period of            Merck and Schering-Plough combined results as if the merger closed            as of January 1, 2009.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">           <b>GAAP<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">           <b>Adjustment<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Supp.\u00a0Comb.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Non-GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1  bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">             <b>% Change <\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(Sep\u00a0YTD\u00a010\u00a0GAAP\u00a0vs<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Supp.\u00a0Comb.\u00a0Non-GAAP <\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Sep YTD 09)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Sep\u00a0YTD\u00a010<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Sep\u00a0YTD\u00a009<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">           <b>Sep YTD 09<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">           <b>Sep YTD 09<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">           <b>TOTAL SALES <\/b><sup><b>(1)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$33,893<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$17,335<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$16,413<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$33,748<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>&#8212;<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">             <b>HUMAN HEALTH <\/b><sup><b>(2)<\/b><\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>29,230<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>16,165<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>13,129<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>29,293<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>&#8212;<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Bone, Resp., Imm., &amp; Dermatology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Singulair         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,638         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,400         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,400         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Remicade         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,004         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,691         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,691         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           18         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Nasonex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           917         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           893         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           893         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Fosamax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           692         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           815         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           815         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -15         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Clarinex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           513         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           564         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           564         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Arcoxia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           284         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           260         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           260         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Asmanex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           156         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           156         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Proventil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           169         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           169         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Cardiovascular<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Zetia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,668         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,625         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,629         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Vytorin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,452         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           57         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,478         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,535         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -5         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Integrilin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           203         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           223         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           223         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Diabetes &amp; Obesity<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Januvia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,710         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,364         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,364         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           25         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Janumet         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           666         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           456         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           456         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           46         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Infectious Disease<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Isentress         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           777         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           518         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           518         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           50         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           PegIntron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           539         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           629         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           629         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -14         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Primaxin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           452         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           493         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           493         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Cancidas         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           437         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           442         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           442         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Invanz         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           249         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           205         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           205         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           21         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Avelox         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           224         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           250         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           250         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -10         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Rebetol         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           166         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           197         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           197         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -16         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Crixivan \/ Stocrin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           148         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           154         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           154         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -4         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Diversified Brands<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Cozaar \/ Hyzaar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,690         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,606         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,606         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -35         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Zocor         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           347         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           419         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           419         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -17         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Propecia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           322         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           318         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           318         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Claritin Rx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           298         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           323         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           323         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Vasotec \/ Vaseretic         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           191         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           226         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           226         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -15         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Proscar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           172         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           219         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           219         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -21         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Remeron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           160         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           174         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           174         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Neurosciences &amp; Ophthalmology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Maxalt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           401         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           418         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           418         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -4         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Cosopt \/ Trusopt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           353         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           370         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           370         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -5         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Subutex \/ Suboxone         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           110         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -29         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Oncology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Temodar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           799         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           781         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           781         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Emend         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           268         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           228         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           228         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           18         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Caelyx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           209         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           195         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           195         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Intron A         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           177         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           177         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -12         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Vaccines<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           ProQuad, M-M-R II and Varivax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,093         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,036         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,036         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Gardasil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           768         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           841         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           841         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           RotaTeq         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           350         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           387         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           387         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -10         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Pneumovax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           220         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           218         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           218         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Zostavax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           136         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           202         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           202         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -32         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Women&#8217;s Health &amp; Endocrine<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           NuvaRing         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           414         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           375         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           375         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           10         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Follistim \/ Puregon         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           389         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           397         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           397         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Implanon         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           165         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           126         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           126         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           31         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl12  bwvertalignt bwalignl\">           Cerazette         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           160         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           134         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           134         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           19         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           <b>Other Human Health <\/b><sup><b>(3)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,009         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           510         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,416         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,926         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>ANIMAL HEALTH<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2,126<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,957<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,957<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>9<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>CONSUMER CARE <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,091<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,048<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,048<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>4<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">           Claritin OTC         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           334         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           342         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           342         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -2         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>Other Revenues <\/b><sup><b>(4)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,446<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,170<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>280<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,450<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>&#8212;<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8 bwpadb1  bwvertalignt bwalignl\">           Astra         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           950         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,082         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,082         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           -12         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           <sup>(1)<\/sup> Only select products are shown.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           <sup>(2) <\/sup>Human Health includes worldwide prescription            pharmaceutical sales and consumer product sales excluding the US and            Canada. Consumer Care includes US and Canada consumer product sales.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           <sup>(3)<\/sup> Includes Human Health products not individually shown            above. Other vaccines sales included in Other Human Health were $207            million and $137 million for the first nine months of 2010 and 2009,            respectively.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           <sup>(4) <\/sup>Other revenues are primarily comprised of alliance            revenue, miscellaneous corporate revenues and third party            manufacturing sales.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"11\">           Note: The Company is providing Supplemental Combined Non-GAAP sales            to reflect the revenues of the company&#8217;s product sales on a            comparable basis to periods prior to the merger. Merck has defined            Supplemental Combined Non-GAAP sales as GAAP sales adjusted to            reflect a full quarter of Merck and Schering-Plough performance as            if the merger closed at the beginning of the periods indicated in            this table. This supplemental information is provided to enhance            investors&#8217; understanding of the company&#8217;s sales performance. This            information should be considered in addition to, but not in lieu of,            sales reported in accordance with GAAP.         <\/td>\n<\/tr>\n<\/table>\n<p><p>       Merck &amp; Co., Inc.<br \/>Media:<br \/>Steven Campanini, 908-423-4291<br \/>or<br \/>David        Caouette, 908-423-3461<br \/>or<br \/>Investor:<br \/>Alex Kelly,        908-423-5185<br \/>or<br \/>Joe Romanelli, 908-423-5088     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.11, for the Quarter Strong Sales of Key Pharmaceutical Products; Solid Performance by Consumer Care and Animal Health Units New Product Launches and Progressing Pipeline Drive Business Momentum On Track to Meet Synergy Target of $3.5 Billion in Annual Savings by End of 2012 Raised Lower End of 2010 Non-GAAP EPS Target Range Due to Solid Year-to-Date Performance; Long-Term Non-GAAP EPS Growth Rate Target Reaffirmed Merck &amp; Co., Inc. (NYSE: MRK) today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve. Third-quarter GAAP EPS was $0.11. Worldwide sales for the third quarter of 2010 were $11.1 billion. Net income1 for the third quarter was $342 million. For the first<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[52,289],"class_list":["post-742046","news_item","type-news_item","status-publish","hentry","tag-financial-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Third-Quarter 2010 Financial Results - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Third-Quarter 2010 Financial Results - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.11, for the Quarter Strong Sales of Key Pharmaceutical Products; Solid Performance by Consumer Care and Animal Health Units New Product Launches and Progressing Pipeline Drive Business Momentum On Track to Meet Synergy Target of $3.5 Billion in Annual Savings by End of 2012 Raised Lower End of 2010 Non-GAAP EPS Target Range Due to Solid Year-to-Date Performance; Long-Term Non-GAAP EPS Growth Rate Target Reaffirmed Merck &amp; Co., Inc. (NYSE: MRK) today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve. Third-quarter GAAP EPS was $0.11. Worldwide sales for the third quarter of 2010 were $11.1 billion. Net income1 for the third quarter was $342 million. For the first\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"29 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-third-quarter-2010-financial-results\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-third-quarter-2010-financial-results\\\/\",\"name\":\"Merck Announces Third-Quarter 2010 Financial Results - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2010-10-29T06:00:00+00:00\",\"dateModified\":\"2026-08-10T17:01:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-third-quarter-2010-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-third-quarter-2010-financial-results\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-third-quarter-2010-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Third-Quarter 2010 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Third-Quarter 2010 Financial Results - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Third-Quarter 2010 Financial Results - Merck.com","og_description":"Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.11, for the Quarter Strong Sales of Key Pharmaceutical Products; Solid Performance by Consumer Care and Animal Health Units New Product Launches and Progressing Pipeline Drive Business Momentum On Track to Meet Synergy Target of $3.5 Billion in Annual Savings by End of 2012 Raised Lower End of 2010 Non-GAAP EPS Target Range Due to Solid Year-to-Date Performance; Long-Term Non-GAAP EPS Growth Rate Target Reaffirmed Merck &amp; Co., Inc. (NYSE: MRK) today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve. Third-quarter GAAP EPS was $0.11. Worldwide sales for the third quarter of 2010 were $11.1 billion. Net income1 for the third quarter was $342 million. For the first","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:14+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"29 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/","name":"Merck Announces Third-Quarter 2010 Financial Results - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2010-10-29T06:00:00+00:00","dateModified":"2026-08-10T17:01:14+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-third-quarter-2010-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Third-Quarter 2010 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a012a4a1-acaf-42e0-862e-77293f96261a","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742046\/revisions"}],"predecessor-version":[{"id":3679184,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742046\/revisions\/3679184"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742046"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}